Infection Control Market Worth $58 billion by 2027, Growing at a CAGR of 13.3% From 2020, Says Meticulous Research®

NEXT STORY
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
PREV STORY
Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

K2M Group Holdings, Inc. to Release Fourth Quarter and Fiscal Year 2015 Financial Results on March 3rd

LEESBURG, Va., Feb. 17, 2016 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq:KTWO), a ...

author_avatar
NASDAQ Market News

Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009

author_avatar
NASDAQ Market News

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough ...

author_avatar
NASDAQ Market News